ログイン

Calculatiom of dose
66問 • 2年前
  • Quinn Karylle Fuentes
  • 通報

    問題一覧

  • 1

    the total quantity of a drug that is to be given to a patient. There's also something known as the relative dose, a dose relative to the patient's body weight.

    Dose.

  • 2

    the frequency at which a dose is administered.

    Dosage.

  • 3

    amounts of drug that may be prescribed within the work of usual medical practice.

    Dosage range.

  • 4

    the amount that may be expected to produce, in adults, the medicinal effect for which it is intended

    Adult dose.

  • 5

    Also known as usual dose.

    Adult dose.

  • 6

    also the priming or loading dose

    Initial dose.

  • 7

    The amount required to attain the desired concentration of the drug in the blood or tissues.

    Initial dose.

  • 8

    Dose that is administered to children Dose applicable to patient’s 65 years and above

    Pediatric and geriatric dose.

  • 9

    The amount which is administered to a patient after the exposure or contraction of an illness

    Therapeutic dose.

  • 10

    The amount administered to a patient before exposure or contraction of the illness

    Prophylactic dose.

  • 11

    Dose required to maintain clinical effectiveness/therapeutic concentration according to dosage regimen

    Maintenance dose.

  • 12

    Pharmaceutical dispensing and compounding calculations use simple arithmetic. (True/False)

    True.

  • 13

    The errors that may arise often are due to •carelessness, •as in improper placing of decimal points, •incorrect conversion from one system of measurement to another, • uncertainty over the system of measurement to be used (True/False)

    True.

  • 14

    very dangerous because of undesirable effect and toxicity.

    Overdose.

  • 15

    decrease effectivity of the drug to the patient.

    Underdose.

  • 16

    In calculation of dose there is a specific patient parameters. l. Patients age and weight. ll.BSA lll. Nutritional and function status lV. pharmacokinetic.

    l,ll,lll,lV.

  • 17

    In neonates and other pediatric patients, The dose individualization (calculaton) is required? ( True/False)

    True.

  • 18

    elderly patients with diminished biologic functions, required a dose individualization or dose calculation. (True/False)

    True.

  • 19

    individuals of all age groups with compromised liver and/or kidney function (and thus reduced ability to metabolize and eliminate drug substances) required a dose individualization or dose calculation. (True/False)

    True.

  • 20

    critically ill patients and patients being treated with highly toxic chemotherapeutic agents. is NOT required a dose individualization or dose calculation. (True/False)

    False.

  • 21

    Certain drugs with a narrow therapeutic window often require individualized dosing based on blood level determinations and therapeutic monitoring. required a dose individualization or dose calculation. (True/False)

    True.

  • 22

    the branch of medicine that deals with disease in children from birth through adolescence.

    Pediatric patients.

  • 23

    if born at less than 37 weeks’ gestation.

    Premature.

  • 24

    from birth to one month.

    Neonates.

  • 25

    1 month to 1 year.

    Infant.

  • 26

    28 days-23 months

    Infant.

  • 27

    2 years through 5 years

    Early childhood.

  • 28

    6 years through 11 years

    Late childhood.

  • 29

    12 years through 18 years.

    Adolescence.

  • 30

    Aside from dosage calculation, there is a need to select pediatric dosage forms that permit more accurate dosing and patient compliance. (True/False)

    True.

  • 31

    Factors affecting dosing pediatrics. l.patients age and weight. ll. overall health status. lll.Stage development of the body. lV. Patient deminish biological function.

    l,ll,lll.

  • 32

    Stage of development of body systems for drug metabolism (liver enzymes) and Drug elimination (renal system) - In neonate, these biologic functions and systems are underdeveloped. (True/False)

    True.

  • 33

    What are the devices that may also used in compliance to medication in pediatrics. l.Calibrated medicine dropper. ll. Premeasured teaspoon (5ml) lll. Nebulizer for inhalation products.

    l,ll,lll.

  • 34

    1 measuring cup =

    8 oz or 240 mL.

  • 35

    1 oz =

    2 Tablespoon or 30 mL.

  • 36

    1 medium-size glass (tumbler size) =

    8 oz or 240 ml.

  • 37

    1 tablespoon (T) =

    3 teaspoons or 15 ml.

  • 38

    1 teaspoon =

    60 drops.

  • 39

    the field that encompasses the management of illness in the elderly.

    Geriatric patient.

  • 40

    65-75 years old.

    Young old.

  • 41

    75-85

    Old.

  • 42

    >85

    Old old.

  • 43

    In pediatrics patient is yherapy is often initiated with a lower-than-usual adult dose (True/ False)

    False.

  • 44

    In geriatric patient Dose adjustment may be required based on the therapeutic response. (True/False)

    True.

  • 45

    The patient’s physical condition may determine the drug dose and the route of administration employed.

    Pediatric patient.

  • 46

    Concomitant drug therapy may affect drug/dose effectiveness. (True/False)

    True.

  • 47

    A drug’s dose may produce undesired adverse effects and may affect patient compliance. (True/False)

    True.

  • 48

    Complex dosage regimens of multiple drug therapy may affect patient compliance. (True/False)

    True.

  • 49

    The age of the patient is a consideration in the determination of drug dosage. (True/False)

    True.

  • 50

    As stated previously, neonates have immature hepatic and renal functions that affect drug response. The elderly, in addition to diminished organ function, frequently have issues of concomitant pathologies and increased sensitivities to drugs. (True/False)

    True.

  • 51

    Today these rules are not in general use because age alone is NO LONGER considered a singularly valid criterion in the determination of accurate dosage for a child, especially when calculated from the usual adult dose, which itself provides wide clinical variations in response. (TRUE/FALSE)

    True.

  • 52

    Currently, when age is considered in determining dosage of a potent therapeutic agent, it is used generally in conjunction with another factor, such as ?.

    Weight.

  • 53

    In situations where the pediatric patient's weight is unknown, for instance, at the point of injury, then Calculation of dose based on age can be safely implemented if their age and the recommended adult dosing are known. (True/False)

    True.

  • 54

    Age-based dosing has demonstrated to be a safe and effective approach. However, caution should be used depending on the class of the drug. (True/False.)

    True.

  • 55

    What is the dose for an 8-month-old infant if the average adult dose of a drug is 250 mg?

    13.33 mg.

  • 56

    If the adult dose of a drug is 100 mg, calculate the approximate dose for a child with a BSA of 0.83 m2

    47.98 mg.

  • 57

    1kg =

    2.2 lb.

  • 58

    1g =

    1000 mg.

  • 59

    1 mg. =

    1000 mcg.

  • 60

    1 m =

    39.37 in.

  • 61

    1 in =

    2.54 cm.

  • 62

    1 ft

    30.48 cm.

  • 63

    The dose of mitomycin injection is 20mg/m2 per day. Determine the daily dose for a patient who weighs 144 lb. and measures 68 in. in height.

    35.4 mg.

  • 64

    The usual initial dose of chlorambucil is 150 mcg/kg of body weight. How many milligrams should be administered to a person weighing 154 lb.?

    10.5 mg.

  • 65

    You receive a prescription ordering Amoxicillin 100mg PO qid. The available amoxicillin in your drugstore is a suspension with a label given below. How many milliliters should the patient receive per day? Dose of the available drug is 228.5mg/5ml.

    8ml /day.

  • 66

    How many capsules, each containing 250 mg of clarithromycin, are needed to provide 50mg/kg/day for 7 days for a person weighing 176 lb.?

    112 Capsules.

  • Cell structure.

    Cell structure.

    Quinn Karylle Fuentes · 28問 · 2年前

    Cell structure.

    Cell structure.

    28問 • 2年前
    Quinn Karylle Fuentes

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    Quinn Karylle Fuentes · 29問 · 2年前

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    29問 • 2年前
    Quinn Karylle Fuentes

    MW

    MW

    Quinn Karylle Fuentes · 45問 · 2年前

    MW

    MW

    45問 • 2年前
    Quinn Karylle Fuentes

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    Quinn Karylle Fuentes · 38問 · 2年前

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    38問 • 2年前
    Quinn Karylle Fuentes

    Density and specific gravity

    Density and specific gravity

    Quinn Karylle Fuentes · 34問 · 2年前

    Density and specific gravity

    Density and specific gravity

    34問 • 2年前
    Quinn Karylle Fuentes

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    Quinn Karylle Fuentes · 18問 · 2年前

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    18問 • 2年前
    Quinn Karylle Fuentes

    Microbial growth

    Microbial growth

    Quinn Karylle Fuentes · 63問 · 2年前

    Microbial growth

    Microbial growth

    63問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 61問 · 2年前

    Introduction.

    Introduction.

    61問 • 2年前
    Quinn Karylle Fuentes

    Microbial control.

    Microbial control.

    Quinn Karylle Fuentes · 97問 · 2年前

    Microbial control.

    Microbial control.

    97問 • 2年前
    Quinn Karylle Fuentes

    States of matter

    States of matter

    Quinn Karylle Fuentes · 100問 · 2年前

    States of matter

    States of matter

    100問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 86問 · 2年前

    Introduction.

    Introduction.

    86問 • 2年前
    Quinn Karylle Fuentes

    Drug development.

    Drug development.

    Quinn Karylle Fuentes · 77問 · 2年前

    Drug development.

    Drug development.

    77問 • 2年前
    Quinn Karylle Fuentes

    CGMP

    CGMP

    Quinn Karylle Fuentes · 9問 · 2年前

    CGMP

    CGMP

    9問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    Quinn Karylle Fuentes · 24問 · 2年前

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    24問 • 2年前
    Quinn Karylle Fuentes

    Powdered & granules

    Powdered & granules

    Quinn Karylle Fuentes · 43問 · 2年前

    Powdered & granules

    Powdered & granules

    43問 • 2年前
    Quinn Karylle Fuentes

    Capsule.

    Capsule.

    Quinn Karylle Fuentes · 24問 · 2年前

    Capsule.

    Capsule.

    24問 • 2年前
    Quinn Karylle Fuentes

    Tablets.

    Tablets.

    Quinn Karylle Fuentes · 23問 · 2年前

    Tablets.

    Tablets.

    23問 • 2年前
    Quinn Karylle Fuentes

    Postlab 5&6

    Postlab 5&6

    Quinn Karylle Fuentes · 29問 · 2年前

    Postlab 5&6

    Postlab 5&6

    29問 • 2年前
    Quinn Karylle Fuentes

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    Quinn Karylle Fuentes · 33問 · 2年前

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    33問 • 2年前
    Quinn Karylle Fuentes

    SEMI SOLID

    SEMI SOLID

    Quinn Karylle Fuentes · 69問 · 2年前

    SEMI SOLID

    SEMI SOLID

    69問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology

    Basic immunology

    Quinn Karylle Fuentes · 60問 · 2年前

    Basic immunology

    Basic immunology

    60問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology (2)

    Basic immunology (2)

    Quinn Karylle Fuentes · 62問 · 2年前

    Basic immunology (2)

    Basic immunology (2)

    62問 • 2年前
    Quinn Karylle Fuentes

    Transdermal

    Transdermal

    Quinn Karylle Fuentes · 44問 · 2年前

    Transdermal

    Transdermal

    44問 • 2年前
    Quinn Karylle Fuentes

    Distribution.

    Distribution.

    Quinn Karylle Fuentes · 43問 · 2年前

    Distribution.

    Distribution.

    43問 • 2年前
    Quinn Karylle Fuentes

    Infectious disease.

    Infectious disease.

    Quinn Karylle Fuentes · 65問 · 2年前

    Infectious disease.

    Infectious disease.

    65問 • 2年前
    Quinn Karylle Fuentes

    Infectious diseases (2)

    Infectious diseases (2)

    Quinn Karylle Fuentes · 79問 · 2年前

    Infectious diseases (2)

    Infectious diseases (2)

    79問 • 2年前
    Quinn Karylle Fuentes

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    Quinn Karylle Fuentes · 35問 · 2年前

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    Quinn Karylle Fuentes · 35問 · 2年前

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic ( Compressed)

    All topic ( Compressed)

    Quinn Karylle Fuentes · 30問 · 2年前

    All topic ( Compressed)

    All topic ( Compressed)

    30問 • 2年前
    Quinn Karylle Fuentes

    All topics (compressed)

    All topics (compressed)

    Quinn Karylle Fuentes · 13問 · 2年前

    All topics (compressed)

    All topics (compressed)

    13問 • 2年前
    Quinn Karylle Fuentes

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    Quinn Karylle Fuentes · 28問 · 2年前

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    28問 • 2年前
    Quinn Karylle Fuentes

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    Quinn Karylle Fuentes · 16問 · 2年前

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    16問 • 2年前
    Quinn Karylle Fuentes

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    Quinn Karylle Fuentes · 26問 · 2年前

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    26問 • 2年前
    Quinn Karylle Fuentes

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    Quinn Karylle Fuentes · 23問 · 2年前

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    23問 • 2年前
    Quinn Karylle Fuentes

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Quinn Karylle Fuentes · 35問 · 2年前

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    35問 • 2年前
    Quinn Karylle Fuentes

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    Quinn Karylle Fuentes · 20問 · 2年前

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    20問 • 2年前
    Quinn Karylle Fuentes

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    Quinn Karylle Fuentes · 33問 · 2年前

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    33問 • 2年前
    Quinn Karylle Fuentes

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    Quinn Karylle Fuentes · 37問 · 2年前

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    37問 • 2年前
    Quinn Karylle Fuentes

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    Quinn Karylle Fuentes · 23問 · 2年前

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    23問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae

    Enterobacteriaceae

    Quinn Karylle Fuentes · 35問 · 2年前

    Enterobacteriaceae

    Enterobacteriaceae

    35問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae.

    Enterobacteriaceae.

    Quinn Karylle Fuentes · 28問 · 2年前

    Enterobacteriaceae.

    Enterobacteriaceae.

    28問 • 2年前
    Quinn Karylle Fuentes

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    Quinn Karylle Fuentes · 31問 · 2年前

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    31問 • 2年前
    Quinn Karylle Fuentes

    Liquid dosage form

    Liquid dosage form

    Quinn Karylle Fuentes · 12問 · 2年前

    Liquid dosage form

    Liquid dosage form

    12問 • 2年前
    Quinn Karylle Fuentes

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    Quinn Karylle Fuentes · 44問 · 2年前

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    44問 • 2年前
    Quinn Karylle Fuentes

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    Quinn Karylle Fuentes · 22問 · 2年前

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    22問 • 2年前
    Quinn Karylle Fuentes

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    Quinn Karylle Fuentes · 40問 · 2年前

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    40問 • 2年前
    Quinn Karylle Fuentes

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    Quinn Karylle Fuentes · 29問 · 2年前

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    29問 • 2年前
    Quinn Karylle Fuentes

    Drug incompatibilities.

    Drug incompatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug incompatibilities.

    Drug incompatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    Drug compatibilities.

    Drug compatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug compatibilities.

    Drug compatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 35問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    35問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 30問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    30問 • 2年前
    Quinn Karylle Fuentes

    SUSPENSION.

    SUSPENSION.

    Quinn Karylle Fuentes · 45問 · 2年前

    SUSPENSION.

    SUSPENSION.

    45問 • 2年前
    Quinn Karylle Fuentes

    Colloidal.

    Colloidal.

    Quinn Karylle Fuentes · 40問 · 2年前

    Colloidal.

    Colloidal.

    40問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    Quinn Karylle Fuentes · 38問 · 2年前

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    38問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY.

    BACTERIOLOGY.

    Quinn Karylle Fuentes · 44問 · 2年前

    BACTERIOLOGY.

    BACTERIOLOGY.

    44問 • 2年前
    Quinn Karylle Fuentes

    Emulsion.

    Emulsion.

    Quinn Karylle Fuentes · 32問 · 2年前

    Emulsion.

    Emulsion.

    32問 • 2年前
    Quinn Karylle Fuentes

    EMULSION

    EMULSION

    Quinn Karylle Fuentes · 42問 · 2年前

    EMULSION

    EMULSION

    42問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    Quinn Karylle Fuentes · 36問 · 2年前

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    36問 • 2年前
    Quinn Karylle Fuentes

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    Quinn Karylle Fuentes · 33問 · 2年前

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    33問 • 2年前
    Quinn Karylle Fuentes

    Mycology.

    Mycology.

    Quinn Karylle Fuentes · 30問 · 2年前

    Mycology.

    Mycology.

    30問 • 2年前
    Quinn Karylle Fuentes

    Mycology 2.0

    Mycology 2.0

    Quinn Karylle Fuentes · 34問 · 2年前

    Mycology 2.0

    Mycology 2.0

    34問 • 2年前
    Quinn Karylle Fuentes

    m

    m

    Quinn Karylle Fuentes · 15問 · 2年前

    m

    m

    15問 • 2年前
    Quinn Karylle Fuentes

    ppr

    ppr

    Quinn Karylle Fuentes · 25問 · 2年前

    ppr

    ppr

    25問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    Quinn Karylle Fuentes · 20問 · 2年前

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    20問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    Quinn Karylle Fuentes · 86問 · 1年前

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    86問 • 1年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    Quinn Karylle Fuentes · 100問 · 1年前

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    100問 • 1年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    Quinn Karylle Fuentes · 19問 · 1年前

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    19問 • 1年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 17問 · 1年前

    Introduction.

    Introduction.

    17問 • 1年前
    Quinn Karylle Fuentes

    Introduction of biochemistry

    Introduction of biochemistry

    Quinn Karylle Fuentes · 76問 · 1年前

    Introduction of biochemistry

    Introduction of biochemistry

    76問 • 1年前
    Quinn Karylle Fuentes

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    Quinn Karylle Fuentes · 56問 · 1年前

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    56問 • 1年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 75問 · 1年前

    Carbohydrates

    Carbohydrates

    75問 • 1年前
    Quinn Karylle Fuentes

    Carbohydrates 1.1

    Carbohydrates 1.1

    Quinn Karylle Fuentes · 31問 · 1年前

    Carbohydrates 1.1

    Carbohydrates 1.1

    31問 • 1年前
    Quinn Karylle Fuentes

    Detect and quality variation.

    Detect and quality variation.

    Quinn Karylle Fuentes · 56問 · 1年前

    Detect and quality variation.

    Detect and quality variation.

    56問 • 1年前
    Quinn Karylle Fuentes

    INTRODUCTION

    INTRODUCTION

    Quinn Karylle Fuentes · 98問 · 1年前

    INTRODUCTION

    INTRODUCTION

    98問 • 1年前
    Quinn Karylle Fuentes

    lab (1-2)

    lab (1-2)

    Quinn Karylle Fuentes · 15問 · 1年前

    lab (1-2)

    lab (1-2)

    15問 • 1年前
    Quinn Karylle Fuentes

    lab 1-2

    lab 1-2

    Quinn Karylle Fuentes · 14問 · 1年前

    lab 1-2

    lab 1-2

    14問 • 1年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    Quinn Karylle Fuentes · 45問 · 1年前

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    45問 • 1年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    Quinn Karylle Fuentes · 35問 · 1年前

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    35問 • 1年前
    Quinn Karylle Fuentes

    Unit 3.

    Unit 3.

    Quinn Karylle Fuentes · 39問 · 1年前

    Unit 3.

    Unit 3.

    39問 • 1年前
    Quinn Karylle Fuentes

    Histamin and kinins

    Histamin and kinins

    Quinn Karylle Fuentes · 70問 · 1年前

    Histamin and kinins

    Histamin and kinins

    70問 • 1年前
    Quinn Karylle Fuentes

    PUD.

    PUD.

    Quinn Karylle Fuentes · 45問 · 1年前

    PUD.

    PUD.

    45問 • 1年前
    Quinn Karylle Fuentes

    ..

    ..

    Quinn Karylle Fuentes · 61問 · 1年前

    ..

    ..

    61問 • 1年前
    Quinn Karylle Fuentes

    Lipids.

    Lipids.

    Quinn Karylle Fuentes · 67問 · 1年前

    Lipids.

    Lipids.

    67問 • 1年前
    Quinn Karylle Fuentes

    lipids.

    lipids.

    Quinn Karylle Fuentes · 71問 · 1年前

    lipids.

    lipids.

    71問 • 1年前
    Quinn Karylle Fuentes

    LAB ✨

    LAB ✨

    Quinn Karylle Fuentes · 93問 · 1年前

    LAB ✨

    LAB ✨

    93問 • 1年前
    Quinn Karylle Fuentes

    Drug discovery.

    Drug discovery.

    Quinn Karylle Fuentes · 87問 · 1年前

    Drug discovery.

    Drug discovery.

    87問 • 1年前
    Quinn Karylle Fuentes

    disease of lipids.

    disease of lipids.

    Quinn Karylle Fuentes · 13問 · 1年前

    disease of lipids.

    disease of lipids.

    13問 • 1年前
    Quinn Karylle Fuentes

    Intro (identify structure)

    Intro (identify structure)

    Quinn Karylle Fuentes · 57問 · 1年前

    Intro (identify structure)

    Intro (identify structure)

    57問 • 1年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 98問 · 1年前

    Carbohydrates

    Carbohydrates

    98問 • 1年前
    Quinn Karylle Fuentes

    Dynamic.

    Dynamic.

    Quinn Karylle Fuentes · 96問 · 1年前

    Dynamic.

    Dynamic.

    96問 • 1年前
    Quinn Karylle Fuentes

    Unit 1

    Unit 1

    Quinn Karylle Fuentes · 32問 · 1年前

    Unit 1

    Unit 1

    32問 • 1年前
    Quinn Karylle Fuentes

    問題一覧

  • 1

    the total quantity of a drug that is to be given to a patient. There's also something known as the relative dose, a dose relative to the patient's body weight.

    Dose.

  • 2

    the frequency at which a dose is administered.

    Dosage.

  • 3

    amounts of drug that may be prescribed within the work of usual medical practice.

    Dosage range.

  • 4

    the amount that may be expected to produce, in adults, the medicinal effect for which it is intended

    Adult dose.

  • 5

    Also known as usual dose.

    Adult dose.

  • 6

    also the priming or loading dose

    Initial dose.

  • 7

    The amount required to attain the desired concentration of the drug in the blood or tissues.

    Initial dose.

  • 8

    Dose that is administered to children Dose applicable to patient’s 65 years and above

    Pediatric and geriatric dose.

  • 9

    The amount which is administered to a patient after the exposure or contraction of an illness

    Therapeutic dose.

  • 10

    The amount administered to a patient before exposure or contraction of the illness

    Prophylactic dose.

  • 11

    Dose required to maintain clinical effectiveness/therapeutic concentration according to dosage regimen

    Maintenance dose.

  • 12

    Pharmaceutical dispensing and compounding calculations use simple arithmetic. (True/False)

    True.

  • 13

    The errors that may arise often are due to •carelessness, •as in improper placing of decimal points, •incorrect conversion from one system of measurement to another, • uncertainty over the system of measurement to be used (True/False)

    True.

  • 14

    very dangerous because of undesirable effect and toxicity.

    Overdose.

  • 15

    decrease effectivity of the drug to the patient.

    Underdose.

  • 16

    In calculation of dose there is a specific patient parameters. l. Patients age and weight. ll.BSA lll. Nutritional and function status lV. pharmacokinetic.

    l,ll,lll,lV.

  • 17

    In neonates and other pediatric patients, The dose individualization (calculaton) is required? ( True/False)

    True.

  • 18

    elderly patients with diminished biologic functions, required a dose individualization or dose calculation. (True/False)

    True.

  • 19

    individuals of all age groups with compromised liver and/or kidney function (and thus reduced ability to metabolize and eliminate drug substances) required a dose individualization or dose calculation. (True/False)

    True.

  • 20

    critically ill patients and patients being treated with highly toxic chemotherapeutic agents. is NOT required a dose individualization or dose calculation. (True/False)

    False.

  • 21

    Certain drugs with a narrow therapeutic window often require individualized dosing based on blood level determinations and therapeutic monitoring. required a dose individualization or dose calculation. (True/False)

    True.

  • 22

    the branch of medicine that deals with disease in children from birth through adolescence.

    Pediatric patients.

  • 23

    if born at less than 37 weeks’ gestation.

    Premature.

  • 24

    from birth to one month.

    Neonates.

  • 25

    1 month to 1 year.

    Infant.

  • 26

    28 days-23 months

    Infant.

  • 27

    2 years through 5 years

    Early childhood.

  • 28

    6 years through 11 years

    Late childhood.

  • 29

    12 years through 18 years.

    Adolescence.

  • 30

    Aside from dosage calculation, there is a need to select pediatric dosage forms that permit more accurate dosing and patient compliance. (True/False)

    True.

  • 31

    Factors affecting dosing pediatrics. l.patients age and weight. ll. overall health status. lll.Stage development of the body. lV. Patient deminish biological function.

    l,ll,lll.

  • 32

    Stage of development of body systems for drug metabolism (liver enzymes) and Drug elimination (renal system) - In neonate, these biologic functions and systems are underdeveloped. (True/False)

    True.

  • 33

    What are the devices that may also used in compliance to medication in pediatrics. l.Calibrated medicine dropper. ll. Premeasured teaspoon (5ml) lll. Nebulizer for inhalation products.

    l,ll,lll.

  • 34

    1 measuring cup =

    8 oz or 240 mL.

  • 35

    1 oz =

    2 Tablespoon or 30 mL.

  • 36

    1 medium-size glass (tumbler size) =

    8 oz or 240 ml.

  • 37

    1 tablespoon (T) =

    3 teaspoons or 15 ml.

  • 38

    1 teaspoon =

    60 drops.

  • 39

    the field that encompasses the management of illness in the elderly.

    Geriatric patient.

  • 40

    65-75 years old.

    Young old.

  • 41

    75-85

    Old.

  • 42

    >85

    Old old.

  • 43

    In pediatrics patient is yherapy is often initiated with a lower-than-usual adult dose (True/ False)

    False.

  • 44

    In geriatric patient Dose adjustment may be required based on the therapeutic response. (True/False)

    True.

  • 45

    The patient’s physical condition may determine the drug dose and the route of administration employed.

    Pediatric patient.

  • 46

    Concomitant drug therapy may affect drug/dose effectiveness. (True/False)

    True.

  • 47

    A drug’s dose may produce undesired adverse effects and may affect patient compliance. (True/False)

    True.

  • 48

    Complex dosage regimens of multiple drug therapy may affect patient compliance. (True/False)

    True.

  • 49

    The age of the patient is a consideration in the determination of drug dosage. (True/False)

    True.

  • 50

    As stated previously, neonates have immature hepatic and renal functions that affect drug response. The elderly, in addition to diminished organ function, frequently have issues of concomitant pathologies and increased sensitivities to drugs. (True/False)

    True.

  • 51

    Today these rules are not in general use because age alone is NO LONGER considered a singularly valid criterion in the determination of accurate dosage for a child, especially when calculated from the usual adult dose, which itself provides wide clinical variations in response. (TRUE/FALSE)

    True.

  • 52

    Currently, when age is considered in determining dosage of a potent therapeutic agent, it is used generally in conjunction with another factor, such as ?.

    Weight.

  • 53

    In situations where the pediatric patient's weight is unknown, for instance, at the point of injury, then Calculation of dose based on age can be safely implemented if their age and the recommended adult dosing are known. (True/False)

    True.

  • 54

    Age-based dosing has demonstrated to be a safe and effective approach. However, caution should be used depending on the class of the drug. (True/False.)

    True.

  • 55

    What is the dose for an 8-month-old infant if the average adult dose of a drug is 250 mg?

    13.33 mg.

  • 56

    If the adult dose of a drug is 100 mg, calculate the approximate dose for a child with a BSA of 0.83 m2

    47.98 mg.

  • 57

    1kg =

    2.2 lb.

  • 58

    1g =

    1000 mg.

  • 59

    1 mg. =

    1000 mcg.

  • 60

    1 m =

    39.37 in.

  • 61

    1 in =

    2.54 cm.

  • 62

    1 ft

    30.48 cm.

  • 63

    The dose of mitomycin injection is 20mg/m2 per day. Determine the daily dose for a patient who weighs 144 lb. and measures 68 in. in height.

    35.4 mg.

  • 64

    The usual initial dose of chlorambucil is 150 mcg/kg of body weight. How many milligrams should be administered to a person weighing 154 lb.?

    10.5 mg.

  • 65

    You receive a prescription ordering Amoxicillin 100mg PO qid. The available amoxicillin in your drugstore is a suspension with a label given below. How many milliliters should the patient receive per day? Dose of the available drug is 228.5mg/5ml.

    8ml /day.

  • 66

    How many capsules, each containing 250 mg of clarithromycin, are needed to provide 50mg/kg/day for 7 days for a person weighing 176 lb.?

    112 Capsules.